Register for our free email digests:
Division of Integra LifeSciences Holdings Corp.
Latest From Nanjing MeiRui Pharma Co. Ltd
Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.
- Rehabilitation Equipment and Devices
- Therapeutic Areas
- Metabolic Disorders
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Integra LifeSciences Holdings Corp.
- Senior Management
Jodie Currie, CEO
Michael D Morrissey, CFO
Nancy Zeller, SVP, Sales & Mktg.
Don Richardson, VP, R&D
- Contact Info
Phone: (303) 321-7755
5161 Ward Rd.
Wheat Ridge, CO 80033
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.